Christopher Webber, MD
Allergy & Immunology · Colorado Springs, CONPI 1386632172
Payments from drug & device makers
Across 797 payments — averaging $438.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$326K
- Amgen$18K
- Phadia US Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$612
- GSK$442
- Grifols USA, LLC$388
- plus $3K from 18 others
Across 1 payment — averaging $940.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$940
What the payments were for
- Consulting fees$31,1129%
- Speaking & faculty fees$275,18579%
- Travel & lodging$24,9217%
- Food & beverage$18,2545%
- Education$740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 521 | $326,199 |
| Amgen | 33 | $18,008 |
| Phadia US Inc. | 2 | $1,320 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $612 |
| GSK | 51 | $442 |
| Grifols USA, LLC | 19 | $388 |
| Sanofi | 13 | $359 |
| ADMA Biomanufacturing LLC | 5 | $320 |
| Novartis | 19 | $286 |
| Teva Pharmaceuticals USA, Inc. | 15 | $283 |
| Optinose US, Inc. | 14 | $277 |
| Genentech USA, Inc. | 16 | $208 |
| Kaleo, Inc. | 7 | $145 |
| Regeneron Healthcare Solutions, Inc. | 7 | $132 |
| Shire North American Group Inc | 7 | $118 |
| CSL Behring | 4 | $117 |
| Pfizer | 5 | $86 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Pharming Healthcare, Inc. | 2 | $48 |
| Circassia Inc. | 3 | $48 |
| Aerin Medical Inc. | 1 | $38 |
| Jubilant Hollisterstier LLC | 1 | $16 |
| Organon | 2 | $16 |
| Biocryst US Sales Co., LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$349,547 in reported general payments places this provider in the 85th percentile of 89 allergy & immunology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 231 | $265,932 |
| XolairOmalizumab | 24 | $143,553 |
| Dupixent PenDupilumab | 20 | $77,617 |
| Spiriva RespimatTiotropium Bromide | 24 | $17,883 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $17,469 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 76 | $15,084 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $14,153 |
| Azelastine Hcl | 444 | $13,729 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $10,215 |
| AirsupraAlbuterol Sulfate/Budesonide | 14 | $7,073 |
| Fluticasone Propionate | 285 | $5,844 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $4,666 |
| Ipratropium Bromide | 102 | $3,682 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $3,418 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 146 | $3,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $442 | $280,086259 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Airsupra | $326,199 | $34,75654 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 89 allergy & immunology providers in Colorado.
Other allergy & immunology in Colorado Springs
- Eric CaplanColorado Springs$488K
- Robert NathanColorado Springs$336K
- Jill HansonColorado Springs$15K
- Sterling KosmachColorado Springs$7K
- Deborah SweetColorado Springs$3K
- Shaila GogateDenver$4M
- Donald LeungDenver$3.5M
- Jeffrey RumbyrtLakewood$2.8M
- Eileen WangDenver$2.3M
- Kevin ObrienThornton$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.